ZYME (Zymeworks Inc.) Stock Analysis - AI Report

Zymeworks Inc. (ZYME) is a publicly traded Healthcare sector company. As of May 20, 2026, ZYME trades at $24.98 with a market cap of $1.80B and a P/E ratio of -6.10. ZYME moved +1.86% today. Year to date, ZYME is -2.51%; over the trailing twelve months it is +99.84%. Its 52-week range spans $9.03 to $29.75. Analyst consensus is strong buy with an average price target of $39.89. Rallies surfaces ZYME's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What is the AI research view on ZYME?

Rallies AI research for ZYME combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.

ZYME Key Metrics

Key financial metrics for ZYME
MetricValue
Price$24.98
Market Cap$1.80B
P/E Ratio-6.10
EPS$-4.08
Dividend Yield0.00%
52-Week High$29.75
52-Week Low$9.03
Volume429.52K
Avg Volume0
Revenue (TTM)$31.62M
Net Income$-236.97M
Gross Margin0.00%

Latest ZYME News

Recent ZYME Insider Trades

  • Hollywood Mark sold 6.12K (~$138.76K) on Jan 12, 2026.
  • Smith Jeffrey T L sold 9.31K (~$211.09K) on Jan 12, 2026.
  • Moore Paul Andrew sold 9.56K (~$216.76K) on Jan 12, 2026.

ZYME Analyst Consensus

11 analysts cover ZYME: 0 strong buy, 11 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $39.89.

Common questions about ZYME

What is the AI research view on ZYME?
Rallies AI research for ZYME combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
What data powers the Rallies AI report for ZYME?
Rallies AI research for ZYME combines live market data, financials, news, analyst context, hedge fund ownership, politician disclosures, insider activity, and risk factors.
Is ZYME research on Rallies investment advice?
No. Rallies provides research, data, and educational context for ZYME. It does not provide personalized investment advice.
ZYME

ZYME